Ocugen has granted Celairis exclusive rights to commercialize OCU400, an investigational gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and ASEAN countries. This deal expands access to a potential one-time treatment for RP in a region with about 725 million people. Ocugen will receive up to $7.1 million in upfront, development, and milestone payments, plus royalties and profit sharing. Celairis will handle regulatory approvals, market access, and commercialization, with OCU400 data expected in early 2027 before regulatory submissions.
The Ocugen and Celairis Therapeutics licensing deal for OCU400 offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 health-sector US stocks, 85 rose and 56 fell. Notable movers include TVTX at USD 50.50 (-2.19%), BNGO at USD 1.18 (+1.72%, 100% sell order activity), and RVTY at USD 163.18 (+1.53%, 100% sell order activity).
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
